The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ten year exclusive distribution agreement

24 May 2011 07:00

RNS Number : 1215H
Omega Diagnostics Group PLC
24 May 2011
 



 

Omega Diagnostics Group PLC

("Omega" or "the Company")

 

Ten year exclusive distribution agreement ("Agreement")

 

Omega, the AIM listed medical diagnostics company, announces that its subsidiary, Cambridge Nutritional Sciences Limited, (CNS) has signed a ten year exclusive distribution agreement with Toyota Tsusho America Inc., (TAI) covering the future sale and distribution of its Food Detective™ product into the US market.

 

Prior to being able to sell Food Detective™ in the US market, the product will first need to undergo a regulatory approval process with the US Food and Drug Administration ("US FDA"). Under the terms of the Agreement, TAI will fund the costs involved in obtaining relevant clinical data and information needed for an intended submission under the US FDA 510(k) clearance procedure which is expected to take 1-2 years.

 

Andrew Shepherd, CEO of Omega, said: "We're very pleased to announce this deal with TAI for distribution of Food Detective™ in the US. The product has been sold in over 50 countries and is well accepted as being a reliable test for those people suffering from the effects of food intolerance. This cost effective test has great potential in the significant US market. The US FDA regulatory approval process is likely to take time and significant resources and having a strong partner such as TAI will greatly assist this process."

 

Commenting on the distribution agreement, William Weiner, COO of TAI, said: "Toyota Tsusho America is excited to work with CNS by providing Food Detective™, which may help meet the needs of Americans who suffer from symptoms related to food intolerance. Food Detective™ provides TAI another proprietary diagnostic test to add to its increasing portfolio. Utilising our knowledge and experience in the diagnostic testing market in the US, along with our superior logistics, and supply chain, we look forward to selling the product through a variety of sales channels, after receiving FDA clearance."

 

 

Further enquiries:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel: 020 7397 8900

Ian Soanes

Elizabeth Bowman

Walbrook PR Limited

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Helen Westaway

Mob: 07841 917 679 or helen.westaway@walbrookpr.com

 

 

Information on TAI:

 

Toyota Tsusho America, Inc. (TAI) is a wholly owned subsidiary of Toyota Tsusho Corporation, which was founded as a trading and supply-chain specialist of the Toyota Group. TAI has been operating in North America since 1961. Over the past four decades, it has evolved from a trader in a limited number of commodities and finished goods to a multi-business enterprise.

 

TAI combines international trading with an expansive range of domestically targeted functions including supply-chain services and intermediate goods processing. Our operating divisions pursue a broad mix of business opportunities related to both industrial and consumer products and services.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRUOOVRARAVUAR
Date   Source Headline
16th Sep 202211:13 amRNSPurchase of Shares by Directors
13th Sep 20227:00 amRNSInvestor presentation and Confirmation of AGM
12th Sep 20227:00 amRNSFinal Results
2nd Sep 202210:15 amRNSHolding(s) in Company
31st Aug 20227:00 amRNSChange of preliminary results date
12th Aug 20227:00 amRNSChange of preliminary results date
8th Aug 20227:00 amRNSConfirmation of Preliminary Results
5th Aug 202212:09 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSCompletion of Sale of the CD4 Business
11th Jul 20227:00 amRNSPayment received
4th Jul 20227:00 amRNSHeads of Terms agreed for Sale of CD4 Business
23rd Jun 20223:13 pmRNSHolding(s) in Company
10th Jun 20227:00 amRNSGrant of share incentive awards
8th Jun 20221:47 pmRNSPDMR/Director Dealing
6th Jun 20222:29 pmRNSResult of General Meeting and Total Voting Rights
1st Jun 20227:00 amRNSResult of Open Offer
13th May 202210:05 amRNSPosting of Circular and Notice of General Meeting
11th May 20223:28 pmRNSHolding(s) in Company
6th May 20227:01 amRNSInvestor presentation
6th May 20227:00 amRNSPlacing, Subscription and Open Offer
7th Apr 20227:00 amRNSTrading Update
11th Mar 20227:00 amRNSUpdate on validation under CTDA legislation
8th Mar 20224:41 pmRNSSecond Price Monitoring Extn
8th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20224:41 pmRNSSecond Price Monitoring Extn
7th Mar 20224:36 pmRNSPrice Monitoring Extension
7th Mar 20223:40 pmRNSResult of General Meeting
7th Mar 202211:03 amRNSConfirmation of Sale of Alva business
1st Mar 20227:00 amRNSResult of Open Offer
18th Feb 20227:00 amRNSInvestor Meeting
14th Feb 20222:06 pmRNSSecond Price Monitoring Extn
14th Feb 20222:01 pmRNSPrice Monitoring Extension
11th Feb 202211:05 amRNSSecond Price Monitoring Extn
11th Feb 202211:00 amRNSPrice Monitoring Extension
11th Feb 20227:01 amRNSFundraising to raise gross proceeds of up to £7m
11th Feb 20227:00 amRNSSale of Alva manufacturing business
10th Feb 20222:06 pmRNSSecond Price Monitoring Extn
10th Feb 20222:00 pmRNSPrice Monitoring Extension
10th Feb 20221:33 pmRNSSpeculation regarding a potential fundraise
8th Feb 20224:41 pmRNSSecond Price Monitoring Extn
8th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSCE-Mark for self-test for VISITECT® COVID-19 test
2nd Feb 20224:41 pmRNSSecond Price Monitoring Extn
2nd Feb 20224:36 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSSpeculation regarding a potential fundraise
19th Jan 20227:00 amRNSDirectorate Change
10th Jan 20223:20 pmRNSConfirmation of detection of Omicron variant
4th Jan 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.